Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 8, 2025
The Broken Brown Egg and Progyny Announce the 2025 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building
GlobeNewswire
·
April 8, 2025
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today …
CORRECTION: ProDentim
GlobeNewswire
·
April 8, 2025
In a release issued under the same headline on April 1, 2025 by ProDentim, please note that the headline has been edited from "ProDentim Reviews (DOCTOR WARNING): Dentists …
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
GlobeNewswire
·
April 8, 2025
- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Overall Response …
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
GlobeNewswire
·
April 8, 2025
Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the …
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health
GlobeNewswire
·
April 8, 2025
WASHINGTON, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the signing …
FibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based Therapeutics
GlobeNewswire
·
April 8, 2025
HOUSTON, April 08, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases …
Hydreight Technologies Partners with Renowned Endocrinologist Dr. Franklin Joseph to Bring Globally Successful Weight Loss Brand to the U.S. via VSDHOne Platform
GlobeNewswire
·
April 8, 2025
VANCOUVER, British Columbia and LAS VEGAS, April 08, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth services in the U.S., is thrilled to …
SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025)
GlobeNewswire
·
April 8, 2025
SANUWAVE is pleased to announce preliminary revenues of $9.1 million to $9.3 million for the first quarter ended March 31, 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2025 revenue increased between 57% and 61% compared to …
3D Bioprinting Market Worth US$2.4 billion | MarketsandMarkets™.
GlobeNewswire
·
April 8, 2025
Delray Beach, FL, April 08, 2025 (GLOBE NEWSWIRE) -- 3D Bioprinting Market, valued at US$1.2 billion in 2023, is forecasted to grow at a robust CAGR of 12.7%, reaching US$1.3 billion in 2024 and an impressive US$2.4 billion by 2029 according to a published …
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
GlobeNewswire
·
April 8, 2025
CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development …
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain
GlobeNewswire
·
April 8, 2025
Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April 08, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device …
Biotricity Recognized by Financial Times as One of 2025’s Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed
GlobeNewswire
·
April 8, 2025
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, …
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
GlobeNewswire
·
April 8, 2025
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for …
OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
GlobeNewswire
·
April 8, 2025
WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide …
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.
GlobeNewswire
·
April 8, 2025
TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Ocugen to Present at the 2025 Cell & Gene Meeting on the Med
GlobeNewswire
·
April 8, 2025
MALVERN, Pa., April 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, …
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 8, 2025
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy …
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
GlobeNewswire
·
April 8, 2025
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82% at 3 years. Seizure freedom with 42% of patients …
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
GlobeNewswire
·
April 8, 2025
JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of …
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
GlobeNewswire
·
April 8, 2025
MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its ASCEND clinical trial for VIA Disc NPTM. The ASCEND study is a …